Peripheral arterial disease.
Hiatt
W R
WR
Department of Medicine, Section of Vascular Medicine, University of Colorado Health Sciences Center, Denver, USA.
Nehler
M R
MR
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000077407:Cilostazol; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000628:therapy; D018450:Disease Progression; D005081:Exercise Therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000150:complications* / Q000188:drug therapy; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D007383:Intermittent Claudication / Q000188:drug therapy* / Q000209:etiology; D007511:Ischemia / Q000209:etiology / Q000628:therapy*; D007866:Leg / Q000098:blood supply*; D016491:Peripheral Vascular Diseases / Q000150:complications / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D012307:Risk Factors; D016540:Smoking Cessation; D013777:Tetrazoles / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D013777:Tetrazoles; D000077407:Cilostazol